All In Biotech

Drug Trial Radar · NCT00660504

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC

Last checked: Nov 19, 2026Latest source record: Jul 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Apr 2008

Primary completion

Feb 2012

Study completion Aug 2012

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.

Conditions

  • Lung Cancer

Interventions

  • Amrubicin HydrochlorideDrug

    Amrubicin Hydrochloride combined with cisplatin

  • Etoposide-Cisplatin combined chemotherapyDrug

    combined chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 1.5 years after last subject enrolled

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Tianjin, China

  • Site not named

    Fuzhou, Fujian, China

  • Site not named

    Lanzhou, Gansu, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Nanchang, Jiangxi, China

  • Site not named

    Changchun, Jilin, China

  • Site not named

    Dalian/Shenyang, Liaoning, China

  • Site not named

    Shenyang, Liaoning, China

  • Site not named

    Xian, Shanxi, China

  • Site not named

    Chengdu, Sichuan, China

  • Site not named

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.